Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company is headquartered in Lexington, Massachusetts.
| Revenue (TTM) | 3,000 |
| Gross Profit (TTM) | 3,000 |
| EBITDA | $-91.76M |
| Operating Margin | 0.00% |
| Return on Equity | -778.00% |
| Return on Assets | -63.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.14 |
| Price-to-Book | 6.75 |
| Price-to-Sales (TTM) | 7575.74 |
| EV/Revenue | 16846.11 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -57.10% |
| Shares Outstanding | $158.65M |
| Float | $136.13M |
| % Insiders | 1.31% |
| % Institutions | 52.47% |
Volatility is currently expanding